Log in

ZIOPHARM Oncology Stock Forecast, Price & News

-0.08 (-3.24 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $2.39
50-Day Range
MA: $2.81
52-Week Range
Now: $2.39
Volume1.82 million shs
Average Volume2.01 million shs
Market Capitalization$511.82 million
P/E RatioN/A
Dividend YieldN/A
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Read More
ZIOPHARM Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ZIOP



Sales & Book Value

Annual Sales$150,000.00
Book Value$0.52 per share


Net Income$-117,800,000.00


Market Cap$511.82 million
Next Earnings Date11/5/2020 (Estimated)
-0.08 (-3.24 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

How has ZIOPHARM Oncology's stock price been impacted by Coronavirus (COVID-19)?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZIOP stock has decreased by 5.9% and is now trading at $2.39.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of ZIOPHARM Oncology?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ZIOPHARM Oncology

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for ZIOPHARM Oncology

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.09). During the same period in the previous year, the firm earned ($0.09) earnings per share.
View ZIOPHARM Oncology's earnings history

What price target have analysts set for ZIOP?

5 brokers have issued 12 month price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $5.50 to $7.50. On average, they anticipate ZIOPHARM Oncology's share price to reach $6.30 in the next year. This suggests a possible upside of 163.6% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology

Who are some of ZIOPHARM Oncology's key competitors?

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (GILD), Opko Health (OPK), Celgene (CELG), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Sangamo Therapeutics (SGMO), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:
  • Dr. Laurence James Neil Cooper, CEO & Director (Age 54)
  • Dr. David M. Mauney M.D., Pres (Age 50)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)
  • Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
  • Mr. David Connolly, VP of Corp. Communications & Investor Relations

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.23%), Goldman Sachs Group Inc. (0.88%), Charles Schwab Investment Management Inc. (0.62%), Nuveen Asset Management LLC (0.50%), Bank of New York Mellon Corp (0.43%) and UBS Group AG (0.26%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology

Which institutional investors are selling ZIOPHARM Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Tudor Investment Corp Et Al, tru Independence LLC, HighTower Advisors LLC, Janney Montgomery Scott LLC, PNC Financial Services Group Inc., Delta Investment Management LLC, and Creative Planning. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper, and Robert Hadfield.
View insider buying and selling activity for ZIOPHARM Oncology

Which institutional investors are buying ZIOPHARM Oncology stock?

ZIOP stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., SG Americas Securities LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Aigen Investment Management LP, Charles Schwab Investment Management Inc., ClariVest Asset Management LLC, and Marshall Wace LLP.
View insider buying and selling activity for ZIOPHARM Oncology

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $2.39.

How big of a company is ZIOPHARM Oncology?

ZIOPHARM Oncology has a market capitalization of $511.82 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-117,800,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is www.ziopharm.com.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.